WO2005030238A1 - Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique - Google Patents
Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique Download PDFInfo
- Publication number
- WO2005030238A1 WO2005030238A1 PCT/FR2004/002422 FR2004002422W WO2005030238A1 WO 2005030238 A1 WO2005030238 A1 WO 2005030238A1 FR 2004002422 W FR2004002422 W FR 2004002422W WO 2005030238 A1 WO2005030238 A1 WO 2005030238A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- motif
- ggxrgdmfgx
- peptides
- crgdmfg
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 58
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 230000001772 anti-angiogenic effect Effects 0.000 title claims description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 15
- -1 3-nitro-2-pyridinesulphenyl group Chemical group 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 6
- 230000007170 pathology Effects 0.000 claims abstract description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims abstract description 3
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 3
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 210000002889 endothelial cell Anatomy 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000012202 endocytosis Effects 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002438 mitochondrial effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 150000001945 cysteines Chemical class 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 150000003573 thiols Chemical group 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims 1
- 101100063069 Caenorhabditis elegans deg-1 gene Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 8
- 108010044426 integrins Proteins 0.000 description 7
- 102000006495 integrins Human genes 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 4
- 102100030497 Cytochrome c Human genes 0.000 description 3
- 108010075031 Cytochromes c Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
- RGOJCHYYBKMRLL-UHFFFAOYSA-N 4-(trifluoromethoxy)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 RGOJCHYYBKMRLL-UHFFFAOYSA-N 0.000 description 1
- 108010009551 Alamethicin Proteins 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- LGHSQOCGTJHDIL-UTXLBGCNSA-N alamethicin Chemical compound N([C@@H](C)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)N[C@H](C(=O)NC(C)(C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CO)CC=1C=CC=CC=1)C(C)C)C(=O)C(C)(C)NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(C)=O LGHSQOCGTJHDIL-UTXLBGCNSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 108010013726 glycyl-arginyl-glycyl-glutamyl-serine Proteins 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SHCXABJSXUACKU-XTXDISFPSA-N isobongkrekic acid Natural products COC(CC=C/C=C/CCC=CCC(C)C=CC(=C/C(=O)O)CC(=O)O)C(=C/C=C(C)/C(=O)O)C SHCXABJSXUACKU-XTXDISFPSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to peptides having in particular an anti-angiogenic activity and to their applications in therapy.
- the inventors' research into therapeutically active peptides led them to develop constructs which have proved to be of great interest with regard to their anti-angiogenic properties.
- the invention therefore relates to such peptides and the use of their therapeutic properties to develop drugs. It thus relates to pharmaceutical compositions containing these peptides as active principle. It also relates to the use of these peptides to manufacture drugs with anti-angiogenic effect, for the treatment of pathologies linked to hypervascularization.
- the peptides according to the invention are characterized in that they are cyclized peptides, corresponding to the sequence SEQ ID No.
- Xi is either a G or a GG whose amino-terminal end is free, alkylated, acylated, in particular acetylated, or comprises a labeling group such as the biotinyl group
- X 3 is either a motif M or a nor-Leucine motif
- X is either a motif or a succession of two di-, tri- or tetra-peptide motifs composed of G or of a combination of G and S, such as GG, GGG, GGGG, GGS, GGGS, GGSGGS, or even
- X 5 is a C motif whose side chain (thiol function) serves as a covalent bonding point with a 3-nitro-2-pyridinesulfenyl group (Npys; Drijfhout et al ., 1988 Int J Peptide protein Res, 32: 161-166) located on the N-terminal end of the following amino acid (L),
- X 6 is either an R motif or a K motif - X 7 is either an R motif, either a KX 8 motif is either an R motif, or a K Xg motif is an aliphatic amino acid (such as G, or A) whose C-terminal end is amid
- peptides contain from 25 to 35 amino acids.
- a peptide of this type responds to the sequence SEQ ID No. 2: GG * CRGDMFG * CGGLLFIHFRIGSRHSRIG ( ⁇ indicates a disulfide bridge connecting the two motifs C).
- Other peptides are as defined above and have an alkyl group at their N-terminal end.
- one or more amino acids are replaced by their dextrorotatory form ( D aa).
- Other peptides according to the invention correspond to SEQ ID No. 1 above, but have one or more peptide bonds to form bioisosteres.
- peptides of the invention include a sequence SEQ ID No. 11: XRGDMF-GX 'exposing the RGD motif by a lactam bridge between the amino acids X (X) -CO-NH- (X'), X and X 'being amino acids such that one carries an acid group, and the other carries an amino.
- Preferred peptides of this group correspond to the sequences SEQ ID No. 12 to SEQ ID No. 23:
- the peptides of the invention are further characterized in that they induce apoptosis of human endothelial cells expressing the ⁇ V ⁇ 3 receptors.
- the specificity of the peptides of the invention results from the addition of the mitochondrio-toxic part to ligands of the integrins to exert a toxicity by the way of the mitochondrio-toxicity, the ligands of the integrins being present for purposes of targeting and not themselves having angiostatic activity.
- the treatment of primary human endothelial cells with doses of peptides of the order of a micromolar leads to a dissipation of the mitochondrial transmembrane potential ( ⁇ m), to the release of mitochondrial cytochrome c, to l 'exposure of phosphatidyl-serine and condensation of nuclear chromatin.
- compositions according to the invention are characterized in that they contain a therapeutically effective amount of at least one peptide, as defined above, in combination with a phar aceutically acceptable vehicle.
- These compositions are advantageously in the dosage forms suitable for their administration by injectable route. Mention will in particular be made of injectable solutions intended for administration by the intravenous route.
- the invention further relates to the use of peptide constructs as defined above for manufacturing anti-angiogenic drugs for the treatment of pathologies due to hypervascularization. Mention will in particular be made of the treatment of solid tumors such as pulmonary tumors, adenomas, melanomas, cancers of the prostate, breast, colon, pancreas, osteosarcomas.
- the invention also applies to the treatment of diabetic retinopathies and polyarthritis.
- the dosages of the administration forms and the treatments will be determined by a person skilled in the art depending on the pathology to be treated and the condition of the patient. Other characteristics and advantages of the invention will be given in the examples which follow relating to the construction SEQ ID No. 2 (hereafter TEAM-VP) SEQ ID No.
- FIGS. 1 to 3 represent, respectively, FIG. 1, the analysis of cytotoxicity on endothelial cells, FIG. 2, the recognition of the CycRGD motif by the integrins ⁇ V ⁇ 3, FIG. 3, the effects of TEAM-VP on isolated itochondria and HUVEC cells.
- the HUVEC cells were pre-incubated or not for 30 min at room temperature with 25 ⁇ M of CycRGD, CycRAD, GRGDS and GRGES peptide before addition of FITC-CycRGD peptide (0.5 ⁇ M), then analyzed by flow cytometry (Figure 2c).
- d Correlation between expression of integrins, binding and toxicity of peptides: The cells HUVEC, HMVECd, MCF-7, MDA, HeLa, HT-29, Jurkat, CEM and PBMC were labeled with the antibodies directed against the integrins ⁇ V ⁇ 3 and ⁇ V ⁇ 5 and analyzed by flow cytometry. The binding of the CycRGD peptide and the induction of apoptosis by TEAM-VP on the different cell types were measured (Figure 2d).
- the FITC-CycRGD and TEAM-VP (FITC) peptides enter the HUVECs and co-locate with the dextran beads (5 hours of co-treatment).
- the entry of TEAM-VP and dextran beads is inhibited by the treatment of sodium azide + deoxyglucose, indicating entry of the peptide by endocytosis.
- No entry of the FITC-CycRAD peptide was observed in the HUVECs, nor was there any entry of the FITC-CycRGD peptide in the HeLa. + TEAM-VP intracellular routing:
- HUVECs treated with TEAM-VP are observed for 8, 24 and 32 hours.
- TEAM-VP revealed with Streptavidin-Texas Red co-distributes with lysosomes (anti-Lamp2-FITC) at 8 h of treatment and seems to leave these organelles at 24 h.
- the isolated mitochondria were incubated with the peptide CycRGD or TEAM-VP in the presence or not of bongkrekic acid (BA, 50 ⁇ M), cyclosporin A (CsA, 10 ⁇ M), and DIDS (8 ⁇ M). Induction of the mitochondrial membrane potential drop: The isolated mitochondria were incubated with 1 ⁇ M of TEAM-VP or its controls (C1, C2, C3), labeled with JC-1 and analyzed by flow cytometry (FIG. 3a),
- HUVEC cells were incubated for 24 hours with 15 ⁇ M of TEAM-VP peptide, CycRGD and C4 then labeled with JC-1 or with an anti-PARP or Annexin-V-FITC and analyzed by flow cytometry (Figure 3d).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04787446A EP1680136A1 (fr) | 2003-09-25 | 2004-09-24 | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
US10/573,576 US20080171697A1 (en) | 2003-09-25 | 2004-09-24 | Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics |
JP2006527447A JP2007506713A (ja) | 2003-09-25 | 2004-09-24 | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 |
IL174547A IL174547A0 (en) | 2003-09-25 | 2006-03-23 | Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0311270A FR2860236B1 (fr) | 2003-09-25 | 2003-09-25 | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
FR0311270 | 2003-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005030238A1 true WO2005030238A1 (fr) | 2005-04-07 |
Family
ID=34307172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2004/002422 WO2005030238A1 (fr) | 2003-09-25 | 2004-09-24 | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080171697A1 (fr) |
EP (1) | EP1680136A1 (fr) |
JP (1) | JP2007506713A (fr) |
FR (1) | FR2860236B1 (fr) |
IL (1) | IL174547A0 (fr) |
WO (1) | WO2005030238A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008004130A2 (fr) * | 2006-06-30 | 2008-01-10 | Theraptosis S.A. | Peptides de ciblage de complexe de port de transition de perméabilité mitochondrial pour induction d'apoptose thérapeutique et applications biologiques |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
EP2289555A1 (fr) * | 2009-08-24 | 2011-03-02 | OrgaNext Research B.V. | Procédé de traitement des faiblesses |
US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
US10357606B2 (en) | 2013-03-13 | 2019-07-23 | Tandem Diabetes Care, Inc. | System and method for integration of insulin pumps and continuous glucose monitoring |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
US10016561B2 (en) | 2013-03-15 | 2018-07-10 | Tandem Diabetes Care, Inc. | Clinical variable determination |
RU2625752C2 (ru) * | 2013-11-19 | 2017-07-18 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Вещество, обладающее антиангиогенной активностью |
US9669160B2 (en) | 2014-07-30 | 2017-06-06 | Tandem Diabetes Care, Inc. | Temporary suspension for closed-loop medicament therapy |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
CN109620949A (zh) * | 2016-03-13 | 2019-04-16 | 曹帅 | 一种用于治疗骨癌的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000049038A2 (fr) * | 1999-02-19 | 2000-08-24 | Ulrich Schubert | Peptides de synthese de la proteine virale regulatrice (vpr) du virus de l'immunodeficience humaine de type 1 (vih1) et leur utilisation |
WO2001092542A2 (fr) * | 2000-05-30 | 2001-12-06 | Ich Productions Limited | Vecteurs ciblant l'integrine avec activite de transfection accrue |
WO2004031768A2 (fr) * | 2002-10-02 | 2004-04-15 | Theraptosis S.A. | Techniques de recherche de modulateurs du fonctionnement mitochondrial et nouveaux modulateurs obtenus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077826A1 (en) * | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
-
2003
- 2003-09-25 FR FR0311270A patent/FR2860236B1/fr not_active Expired - Fee Related
-
2004
- 2004-09-24 WO PCT/FR2004/002422 patent/WO2005030238A1/fr active Application Filing
- 2004-09-24 JP JP2006527447A patent/JP2007506713A/ja active Pending
- 2004-09-24 EP EP04787446A patent/EP1680136A1/fr not_active Withdrawn
- 2004-09-24 US US10/573,576 patent/US20080171697A1/en not_active Abandoned
-
2006
- 2006-03-23 IL IL174547A patent/IL174547A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000049038A2 (fr) * | 1999-02-19 | 2000-08-24 | Ulrich Schubert | Peptides de synthese de la proteine virale regulatrice (vpr) du virus de l'immunodeficience humaine de type 1 (vih1) et leur utilisation |
WO2001092542A2 (fr) * | 2000-05-30 | 2001-12-06 | Ich Productions Limited | Vecteurs ciblant l'integrine avec activite de transfection accrue |
WO2004031768A2 (fr) * | 2002-10-02 | 2004-04-15 | Theraptosis S.A. | Techniques de recherche de modulateurs du fonctionnement mitochondrial et nouveaux modulateurs obtenus |
Non-Patent Citations (7)
Title |
---|
COSTANTINI P ET AL: "Mitochondrion as a novel target of anticancer chemotherapy.", JOURNAL OF THE NATIONAL CANCER INSTITUTE. 5 JUL 2000, vol. 92, no. 13, 5 July 2000 (2000-07-05), pages 1042 - 1053, XP009008236, ISSN: 0027-8874 * |
HAUBNER R ET AL: "STEREOISOMERIC PEPTIDE LIBRARIES AND PEPTIDOMIMETICS FOR DESIGNING SELECTIVE INHIBITORS OF THE ALPHAVBETA3 INTEGRIN FOR A NEW CANCER THERAPY", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 36, 1997, pages 1375 - 1389, XP001008836, ISSN: 0570-0833 * |
KAWAGUCHI MICHIYA ET AL: "A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDfdbdV-) is the potent inhibitor of angiogenesis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 288, no. 3, 2 November 2001 (2001-11-02), &, pages 711 - 717, XP002274582, ISSN: 0006-291X * |
KUMAR C CHANDRA: "Integrin alphavbeta3 as a therapeutic target for blocking tumor-induced angiogenesis.", CURRENT DRUG TARGETS, vol. 4, no. 2, February 2003 (2003-02-01), &, pages 123 - 131, XP009027835, ISSN: 1389-4501 * |
RUEGG C ET AL: "Vascular integrins: Pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis.", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 60, no. 6, June 2003 (2003-06-01), &, pages 1135 - 1157, XP001180259, ISSN: 1420-682X * |
SCHRAA ASTRID J ET AL: "Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.", JOURNAL OF CONTROLLED RELEASE : OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY. 4 OCT 2002, vol. 83, no. 2, 4 October 2002 (2002-10-04), pages 241 - 251, XP004383634, ISSN: 0168-3659 * |
WESTLIN W F: "Integrins as targets of angiogenesis inhibition.", CANCER JOURNAL (SUDBURY, MASS.) 2001 NOV-DEC, vol. 7 Suppl 3, November 2001 (2001-11-01), pages S139 - S143, XP009027919, ISSN: 1528-9117 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008004130A2 (fr) * | 2006-06-30 | 2008-01-10 | Theraptosis S.A. | Peptides de ciblage de complexe de port de transition de perméabilité mitochondrial pour induction d'apoptose thérapeutique et applications biologiques |
WO2008004130A3 (fr) * | 2006-06-30 | 2008-07-31 | Theraptosis S A | Peptides de ciblage de complexe de port de transition de perméabilité mitochondrial pour induction d'apoptose thérapeutique et applications biologiques |
Also Published As
Publication number | Publication date |
---|---|
US20080171697A1 (en) | 2008-07-17 |
FR2860236B1 (fr) | 2006-01-06 |
FR2860236A1 (fr) | 2005-04-01 |
EP1680136A1 (fr) | 2006-07-19 |
JP2007506713A (ja) | 2007-03-22 |
IL174547A0 (en) | 2006-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005030238A1 (fr) | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique | |
Greenwood et al. | The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis | |
US9169290B2 (en) | Peptides and their use | |
JP7095037B2 (ja) | アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果 | |
CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
ES2327986T3 (es) | Liberacion intranuclear de compuestos dirigida por la proteina de choque termico de 70 kd. | |
EP3166959A1 (fr) | Peptides de ciblage qui lient s. mutans, constructions comprenant lesdits peptides et utilisations correspondantes | |
JP2008501310A6 (ja) | 胃腸障害の治療のための方法および組成物 | |
JP2008501310A (ja) | 胃腸障害の治療のための方法および組成物 | |
JP2017526640A5 (fr) | ||
Tati et al. | Histatin 5-spermidine conjugates have enhanced fungicidal activity and efficacy as a topical therapeutic for oral candidiasis | |
US7306944B2 (en) | Advanced cell-transducing transport domain-target protein-transport domain fusion protein and uses thereof | |
Borgne-Sanchez et al. | Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of αvβ3-expressing endothelial cells | |
AU2004247286A1 (en) | Peptides enhancing CEH activity or inhibiting ACAT activity, pharmaceutical compositions comprising these peptides and their use in the treatment of atherosclerosis | |
FR2622587A1 (fr) | Peptide lysyl-arginyl-aspartyl-serine et ses applications en tant que medicament, notamment antithrombotique | |
Montagnani Marelli et al. | Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor | |
JP6924151B2 (ja) | 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法 | |
US20230174582A1 (en) | Vipr2 antagonist peptide | |
WO2020230780A1 (fr) | PEPTIDE INHIBITEUR DE Ras | |
WO2003026700A2 (fr) | Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central | |
Soleimani | Expression, regulation and the role of SLC26 Cl−/HCO3− exchangers in kidney and gastrointestinal tract | |
WO2016063969A1 (fr) | Peptide de liaison à l'hémagglutinine | |
JP2013071904A (ja) | 抗インフルエンザウイルス活性を有するペプチド | |
Azmi et al. | Self-assembling lipopeptides with a potent activity against Gram-positive bacteria, including multidrug resistant strains | |
JP2016515137A (ja) | アポリポタンパク質模倣体及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 174547 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006527447 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004787446 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004787446 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10573576 Country of ref document: US |